source
- Helus Pharma reports Phase 3 depression trial shows symptom improvement but safety concerns lingerHelus Pharma, a psychedelics-focused company, announced results of its Phase 3 trial for its lead depression drug. The trial showed the drug produced greater improvement in depression symptoms com…
- Johnson & Johnson agrees to acquire eye-disease biotech Ollin Biosciences for up to $3.3 billionJohnson & Johnson announced Monday that it will purchase Ollin Biosciences, a biotech focused on eye diseases. The transaction is valued at up to $3.3 billion, representing one of the larger recen…